vTv Therapeutics

We’ve come a long way in the fight against diabetes, and this #AmericanDiabetesMonth, the ADA’s timeline highlights both the milestones achieved and important work still ahead. vTv is dedicated to supporting efforts that advance care and empower people living with diabetes. https://bit.ly/484AmDF

Members of the vTv team recently showed up in Kernersville, NC for the Breakthrough T1D Walk to help fuel advances in type 1 diabetes. At the walk, Chief Scientific Officer Carmen Valcarce and Vice President and Head of Clinical Development Operations Jennifer Freeman joined Breakthrough T1D Senior Chapter Director – Piedmont Triad Chapter Eleanor Schaffner-Mosh on stage, emphasizing vTv's support of the organization's mission and the Company's commitment to research seeking to improve the lives of people living with T1D. vTv was proud to be part of this amazing event. #T1D #VTV #diabetes

Thanks to advances in technology over the last couple of decades, daily management of type 1 diabetes (T1D) has improved drastically.   Despite this, a serious medical risk persists – hypoglycemia, or low blood sugar. Even with devices like continuous glucose monitors (CGM), insulin pumps, and automated insulin delivery systems, the average person with T1D may experience low blood glucose as often as twice per week. In addition to its physical impact, hypoglycemia may cause mental distress. A 2023 study in BMJ Open Diabetes Research & Care found that 30 percent of people with T1D experience high fear of hypoglycemia (FoH) and reported higher A1c.   To learn more about hypoglycemia, watch this educational video from Breakthrough T1D: https://bit.ly/43fX4pt   #T1D #VTV 

#DYK: Even with the latest diabetes technologies like continuous glucose monitoring (CGM) and automated insulin delivery (AID) devices, many people with type 1 diabetes still struggle to reach recommended glycemic targets and experience significant hypoglycemia. A recent study published in Diabetes Care highlights the need for novel therapies that can further improve glycemic control and reduce hypoglycemia for those living with type 1 diabetes. We recognize the importance of advancing therapies with the potential to reduce the frequency of hypoglycemia and help individuals better manage their glucose levels. In a Phase 2 study, vTv's glucokinase activator, cadisegliatin, showed a meaningful reduction in symptomatic hypoglycemic events, highlighting its potential to improve the lives of those with T1D. Building on these promising results, and supported by the FDA’s Breakthrough Therapy designation, vTv is now conducting the Phase 3 CATT1 trial, evaluating cadisegliatin in adults with type 1 diabetes. The study’s primary endpoint is the incidence of level 2 and 3 hypoglycemic events, with a key secondary endpoint assessing reduction in hemoglobin A1C. Read more from Diabetes Care: http://bit.ly/3WsRGvg Learn more about vTv's ongoing Phase 3 CATT1 Study: https://bit.ly/4nSHmJ2 #T1D #VTVT Cadisegliatin is under investigation, and the safety and efficacy have not been established. There is no guarantee that this product will receive health authority approval or become commercially available for the use being investigated.

Sugary foods are not the only cause of blood glucose highs and lows in people with type 1 diabetes. Did you know there are actually up to 42 variables that may impact a person’s blood glucose levels? Stress, caffeine, exercise, and even sunburn may impact blood glucose levels! There is no one-size-fits-all approach to dosing insulin given the many factors that affect blood sugar. People with T1D who are not hitting their glucose targets should discuss their specific concerns with a healthcare provider who can help provide strategies for managing both hypoglycemia and hyperglycemia. During World Diabetes Day, learn more about some of the factors that impact glucose levels and use this list from The diaTribe Foundation as a conversation starter for speaking with a doctor: https://bit.ly/3W5YChV #WorldDiabetesDay #diabetes #endocrinology #insulinresistance

Our Chief Medical Officer Thomas Strack, MD, recently represented #VTV at the Diabetes Technology Meeting to hear about the latest in technology and diabetes management. Read Thomas’ LinkedIn article below, where he shares his insights on the positive impact of technology for people with #T1D and where gaps in care remain. #DiabetesTechnologyMeeting #DTM2025 #hypoglycemia 

We appreciate organizations like T1D Exchange that are bringing attention to the impact of type one diabetes on a person’s overall well-being. For someone with T1D, managing their health is like driving along a narrow, winding road as they are constantly dealing with hyperglycemia and hypoglycemia, each with its challenges. Ongoing educational efforts and new therapies in development provide hope that we can help make that road more straightforward, allowing people to more easily navigate those twists and turns. 

According to the American Diabetes Association, diabetes is rapidly becoming one of the most common chronic diseases globally, with hypoglycemia being a significant barrier for optimal T1D management. Learn more about diabetes from ADA and follow along on their social channels this November for more educational resources about this disease that impacts far too many lives.    #AmericanDiabetesMonth 

#NEWS: #VTV today reported financial results for the third quarter of 2025 and provided an update on recent corporate developments, including the first participant randomized in its CATT1 trial for type 1 diabetes, the expansion of the U.S. patent estate for cadisegliatin, and the closing of an $80 million private placement financing.    Read the full release here: https://bit.ly/4oVcQyi   #VTVT #T1D    Cadisegliatin is under investigation, and the safety and efficacy have not been established. There is no guarantee that this product will receive health authority approval or become commercially available for the use being investigated. 

vTv is proud to be a sponsor of tomorrow’s Breakthrough T1D Walk at Triad Park in Kernersville, NC, and at Manhattanville University in Purchase, NY! Breakthrough T1D hosts walks throughout the world to help raise awareness of type 1 diabetes and generate vital financial support for research efforts in the field. Our Chief Medical Officer Thomas S., Chief Scientific Officer Carmen Valcarce, and Vice President and Head of Clinical Development Operations Jennifer Freeman will be among those walking to make an impact in the T1D community. Join us in helping to improve the lives of people with type 1 diabetes! Register for a local Breakthrough T1D Walk near you or participate virtually. ⬇️ #T1D #VTV #diabetes